These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36942344)

  • 21. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003.
    Feja K; McNelley E; Tran CS; Burzynski J; Saiman L
    Pediatr Infect Dis J; 2008 Oct; 27(10):907-12. PubMed ID: 18756183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China.
    Fang MT; Su YF; An HR; Zhang PZ; Deng GF; Liu HM; Mao Z; Zeng JF; Li G; Yang QT; Wang ZY
    BMC Infect Dis; 2021 Sep; 21(1):1015. PubMed ID: 34583653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and attribute analysis of key stakeholders who influence multidrug-resistant tuberculosis prevention and control in China.
    Chen B; Bao H; Chen X; Liu K; Peng Y; Wang W; Wang F; Jiang J; Xu B
    Infect Dis Poverty; 2021 Aug; 10(1):108. PubMed ID: 34384503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
    Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
    BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up.
    Harries AD; Kumar AMV; Satyanarayana S; Takarinda KC; Timire C; Dlodlo RA
    Expert Rev Respir Med; 2020 Feb; 14(2):195-208. PubMed ID: 31760848
    [No Abstract]   [Full Text] [Related]  

  • 27. Multi-drug resistant tuberculosis burden and risk factors: an update.
    Marahatta SB
    Kathmandu Univ Med J (KUMJ); 2010; 8(29):116-25. PubMed ID: 21209520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of tuberculosis underreporting in Greece through comparison with anti-tuberculosis drug consumption.
    Lytras T; Spala G; Bonovas S; Panagiotopoulos T
    PLoS One; 2012; 7(11):e50033. PubMed ID: 23185524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.
    Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG
    BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventive therapy for latent tuberculosis infection-the promise and the challenges.
    Fox GJ; Dobler CC; Marais BJ; Denholm JT
    Int J Infect Dis; 2017 Mar; 56():68-76. PubMed ID: 27872018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Annual progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis in 2022].
    Yu JJ; Tang SJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Jan; 46(1):62-66. PubMed ID: 36617931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2011: the year in review. part I: tuberculosis.
    Chang KC; Nuermberger EL
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):740-8. PubMed ID: 22613685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China.
    Zhu QQ; Wang J; Sam NB; Luo J; Liu J; Pan HF
    Med Sci Monit; 2022 Apr; 28():e935334. PubMed ID: 35437301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High frequency of azole resistant Candida spp. colonization among presumptive multidrug resistant tuberculosis (MDR-TB) patients.
    Darma S; Ambara A; Aman AT; Annisa L; Nurrokhman ; Nuryastuti T; Wibawa T
    PLoS One; 2020; 15(11):e0242542. PubMed ID: 33212470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuberculosis: Common Questions and Answers.
    Hartman-Adams H; Gerbo RM; George S
    Am Fam Physician; 2022 Sep; 106(3):308-315. PubMed ID: 36126013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa.
    Salaam-Dreyer Z; Streicher EM; Sirgel FA; Menardo F; Borrell S; Reinhard M; Doetsch A; Cudahy PGT; Mohr-Holland E; Daniels J; Dippenaar A; Nicol MP; Gagneux S; Warren RM; Cox H
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0036421. PubMed ID: 34460307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.